Free tool
FAERS Monitor: Cardura
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019668 or its brand name (Cardura, Doxazosin Mesylate). Reports on generic versions are filed under their own applications.
Reports
35,916
Serious
29,638
83% of reports
Hospitalization
15,217
Death reported
3,084
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,987
- fatigue1,755
- dizziness1,719
- diarrhoea1,694
- drug ineffective1,605
- nausea1,490
- hypotension1,309
- acute kidney injury1,268
- headache1,268
- asthenia1,247
- hypertension1,159
- drug interaction1,118
- vomiting1,060
- fall1,017
- malaise1,006
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 687 |
| 2005 | 703 |
| 2006 | 718 |
| 2007 | 747 |
| 2008 | 704 |
| 2009 | 853 |
| 2010 | 1,096 |
| 2011 | 1,351 |
| 2012 | 1,374 |
| 2013 | 1,270 |
| 2014 | 1,597 |
| 2015 | 2,001 |
| 2016 | 2,146 |
| 2017 | 2,066 |
| 2018 | 2,559 |
| 2019 | 2,741 |
| 2020 | 2,104 |
| 2021 | 1,894 |
| 2022 | 1,929 |
| 2023 | 1,951 |
| 2024 | 2,070 |
| 2025 | 1,955 |
| 2026 | 1,399 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,018,243 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 1,268 | 4.9 | 4.6 | 3,909 |
| drug interactionSignal | 1,118 | 4.1 | 3.9 | 2,670 |
| hypotensionSignal | 1,309 | 3.8 | 3.6 | 2,755 |
| hypertensionSignal | 1,159 | 3.2 | 3.0 | 1,777 |
| dyspnoeaSignal | 1,987 | 2.1 | 2.0 | 1,108 |
| dizzinessSignal | 1,719 | 2.0 | 1.9 | 905 |
| asthenia | 1,247 | 1.9 | 1.8 | 580 |
| fall | 1,017 | 1.8 | 1.7 | 360 |
| diarrhoea | 1,694 | 1.5 | 1.5 | 328 |
| malaise | 1,006 | 1.3 | 1.3 | 90 |
| vomiting | 1,060 | 1.3 | 1.2 | 84 |
| fatigue | 1,755 | 1.3 | 1.3 | 141 |
| headache | 1,268 | 1.2 | 1.1 | 37 |
| nausea | 1,490 | 1.1 | 1.0 | 15 |
| drug ineffective | 1,605 | 0.7 | 0.7 | 198 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.